Pushing Boundaries to Revolutionize Chronic Inflammation Therapy

By Joe Petroziello -- Pharmaceutical Executive June 13, 2024 Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions. During BIO International Convention 2024, CEO Dave Bearss, PhD, of Halia...

Utah Founder 100 Honorees Named

Venture Capital Podcast has released their Founder 100 honoree list for Utah. It is a crowd-nominated, peer-voted list of the state's top founders in terms of their attractiveness to investors. The honorees and a large group of investors will meet this evening in a...

Utah executives’ top 10 business apps

By Brittny Goodsell -- Utah Business Magazine David Bearss, CEO of Halia Therapeutics, says his company uses Carta to manage multiple things. “Biotech companies are always in need of large capital raises to support the expenses from clinical development of new...

Halia: Leveraging RAB10 as a new lens on the NLRP3 inflammasome

BioCentury Guided by human variation in the GTPase RAB10, Utah-based company seeks to disrupt inflammasome assemblyBY RICHARD GUY, BIOPHARMA ANALYSTMay 23, 2024 Halia has a new take on drugging the NLRP3 inflammasome that centers on exploiting RAB10 biology to control...

AI Versus Alzheimer’s

By Heather Bergerson -- Utah Business Magazine Utah-based companies Halia Therapeutics and Canary Speech are collaborating to revolutionize how Alzheimer's disease can be monitored and treated. https://bit.ly/3z2AhkH

Longevity.Technology – Waging War on Chronic Inflammation

January 11th, 2024 Author: Danny Sullivan Dr. David Bearss was featured in Longevity.Technology discussing Halia Therapeutics moving into multiple Phase 2 trials for chronic inflammation and whether the company may have created a ‘longevity drug.’ Fresh from...

Halia Therapeutics CEO David Bearss featured on Bioworld Podcast

One aspect of 2023 our group of executives completely agreed on: the past year was tough financially. And they all foresee a more vibrant year ahead for the market. Giving all of them hope were technological breakthroughs such as artificial intelligence, game changing...

Halia Therapeutics to test HT-6184 in MDS patients for first time

The Phase II trial of HT-6184 will enroll around 50 patients with MDS who are or are on the borderline of being transfusion-dependent. Halia Therapeutics is looking to start a Phase II trial of its pipeline candidate HT-6184 in myelodysplastic syndrome (MDS) early...

Utah Business: How David J. Bearss co-founded Halia Therapeutics

Starting a company is interesting. I’m a scientist by training and have often considered myself the world’s most reluctant entrepreneur. Halia Therapeutics is the sixth company I’ve started, but most of the time, I still think of myself as the guy who used...

David Bearss is featured in Biosphere Magazine

David Bearss’ passion for drug discovery has guided his noteworthy career as a dynamic leader who integrates scientific and business interests to deliver new medicines to patients. That passion is still evident today as he gives back to the industry he loves, making a difference with bold initiatives to improve health and change the face of Utah’s life sciences ecosystem.

Contact Us

Corporate Headquarters

3900 N. Traverse Mountain Blvd., Suite 100
Lehi, Utah 84043
United States

info@haliatx.com |  +1 (385) 355-4315